Express News | Emergent BioSolutions Shares up 4.3% on Gaining Commercial Rights for Hikma's Opioid Overdose Treatment
Express News | Emergent BioSolutions Gains Exclusive Commercial Rights to Kloxxado® (Naloxone Hci) Nasal Spray From Hikma Pharmaceuticals
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO (Naloxone HCI) Nasal Spray From Hikma Pharmaceuticals
Emergent BioSolutions Receives $16.7M Contract Option To Continue Development Collaboration With BARDA On Ebanga Treatment For Ebola
Express News | Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration With Barda on Ebanga™ (Ansuvimab-Zykl) Treatment for Ebola
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration With BARDA on Ebanga (Ansuvimab-zykl) Treatment for Ebola
H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $15
Emergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
Express News | Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense With Biothrax® (Anthrax Vaccine Adsorbed)
Vaccine Stocks Gain Amid Uptick in Flu, COVID-19, RSV
Emergent BioSolutions (NYSE:EBS) Shareholder Returns Have Been Solid, Earning 285% in 1 Year
Why Emergent BioSolutions Stock Blasted Higher Today
Sector Update: Health Care Stocks Lower Monday Afternoon
Crude Oil Gains 1%; Chicago PMI Falls In December
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Emergent BioSolutions Analyst Ratings
H.C. Wainwright Initiates Emergent BioSolutions(EBS.US) With Buy Rating, Announces Target Price $15
Express News | Emergent BioSolutions Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $15